To keep drug prices high, pharma has been piling up the patents
Source Entity
Beth Mole
A new study reveals that pharmaceutical companies are significantly extending drug patent lifespans by filing multiple 'nonprimary' patents. This strategy, which triples patent counts per drug, contributes to sustained high prescription costs for American consumers.
The Strategy of Patent Thicketing
The pharmaceutical industry has increasingly turned to a practice known as "patent thicketing" to maintain high profit margins on prescription medications. According to a recent study published in JAMA, the average number of patents per small-molecule drug has surged from 2.1 in 1990 to 6.9 by 2019. This three-fold increase represents a deliberate effort by companies to extend their market exclusivity well beyond the standard initial patent term.
The Rise of Nonprimary Patents
The core of this issue lies in the proliferation of "nonprimary" patents. Unlike the original patent, which protects the active pharmaceutical ingredient (API), these secondary patents cover peripheral elements such as dosage forms, delivery mechanisms, or minor chemical variations. While these filings are technically legal, their cumulative effect creates a formidable barrier to entry for generic competitors, effectively blocking lower-cost alternatives from reaching the market for years.
Extending Market Exclusivity
By layering these secondary patents, pharmaceutical manufacturers have successfully extended the period of patent protection for individual drugs from two years to over six years in many instances. This extension is a critical factor in the broader healthcare cost crisis in the United States. When generics are prevented from entering the market due to active "patent walls," consumers are denied the significant price reductions that competition typically provides, forcing them to pay premium prices for longer durations.
Implications for Healthcare Affordability
The exploitation of the patent system stands as a major driver of why Americans pay substantially more for prescription medicines than patients in other peer nations. This systemic issue shifts the financial burden onto consumers and insurance providers, exacerbating the already high cost of healthcare. The study highlights that this is not merely a byproduct of innovation, but a calculated business strategy designed to maximize revenue.
Future Trends and Regulatory Outlook
The findings from the JAMA study provide a clear empirical basis for ongoing policy discussions regarding drug pricing reform. As legislators look to address the affordability of prescription drugs, the focus is likely to shift toward closing loopholes that allow for the excessive stacking of patents. Without meaningful regulatory intervention to curb the practice of patent thicketing, the trend of extended market exclusivity is expected to continue, maintaining high barriers for affordable generic entry.